THERAPEUTIC COMPOUNDS AND METHODS Russian patent published in 2022 - IPC C07K14/54 C07K14/55 C07K16/28 C07K16/30 A61P35/00 

Abstract RU 2770001 C2

FIELD: pharmaceuticals.

SUBSTANCE: group of inventions relates to construction and use of molecules of trispecific killer-attracting agents. Proposed is a compound for treating a malignant tumour expressing a tumour antigen, containing an NK-attracting domain containing amino acid residues 1-240 SEQ ID No.1 or amino acid residues 19-140 SEQ ID No.14; an NK-activating domain containing an amino acid sequence SEQ ID No.15 or amino acid sequence SEQ ID No.15 containing an amino acid substitution N72D or an amino acid substitution N72A; a first flanking polypeptide binding the NK-attracting domain and the NK-activating domain; a guiding domain, binding specifically to said tumour antigen; and a second flanking polypeptide binding the NK-activating domain and the guiding domain. In particular, proposed is a compound containing an amino acid sequence SEQ ID No.1 or SEQ ID No. 14.

EFFECT: trispecific killer-attracting agents induce NK cell proliferation and prolonged survival thereof, can serve as an ADCC mediator, and allow NK cells to be grown without the need for extracorporeal genetic modification and gene therapy.

24 cl, 22 dwg, 3 tbl, 4 ex

Similar patents RU2770001C2

Title Year Author Number
NK INVOLVING MOLECULES AND METHODS OF THEIR USE 2019
  • Miller, Jeffrey, S.
  • Felices, Martin
  • Vallera, Daniel Attilio
  • Lenvik, Todd, R.
RU2812481C2
CHIMERIC ANTIGEN RECEPTORS TARGETED B-CELL MATURATION ANTIGEN 2013
  • Kokhenderfer Dzhejms Nobl
RU2766608C2
METHODS FOR PRODUCING CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR 2015
  • Bedoya Felipe
  • Ghassemi Saba
  • June Carl H.
  • Levine Bruce L.
  • Melenhorst Jan J.
  • Milone Michael C.
  • Powell Daniel J. Jr.
  • Zheng Zoe
RU2751362C2
T- CELLS WITH COSTIMULATING CHIMERIC ANTIGEN RECEPTOR TARGETING IL13Rα2 2015
  • Braun Kristin E.
  • Formen Stiven Dzh.
RU2749922C2
T-CELLS MODIFIED WITH CHIMERIC ANTIGEN RECEPTOR TARGETED TO CS1 FOR TREATMENT OF AMYLOIDOSIS AL 2018
  • Van, Syuli
  • Formen, Stiven Dzh.
RU2774895C2
COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN EXPRESSION 2017
  • Golosov, Andrei
  • Guimaraes, Carla
  • Motz, Gregory
  • Milone, Michael
  • Ellebrecht, Christoph, T.
  • Payne, Aimee, S.
RU2795467C2
CHIMERIC ANTIGENIC (CAR) RECEPTOR AGAINST CD123 FOR USE IN TREATING MALIGNANT TUMORS 2015
  • Brogdon, Jennifer
  • Gill, Saar
  • Glass, David
  • Kenderian, Saad
  • Loew, Andreas
  • Mannick, Joan
  • Milone, Michael
  • Murphy, Leon
  • Porter, David, L.
  • Ruella, Marco
  • Wang, Yongqiang
  • Wu, Qilong
  • Zhang, Jiquan
RU2724999C2
T-CELLS MODIFIED WITH A CHIMERIC ANTIGEN RECEPTOR TARGETING CS1 2015
  • Formen Stiven Dzh.
  • Van Syuli
RU2727451C2
THERAPEUTIC PRODUCT CONTAINING IL-33 ANTAGONIST FOR THE TREATMENT OF ENDOMETRIOSIS 2018
  • Yoshimoto, Tomohiro
  • Palumbo, M. Joseph
  • Stone, I. Violetta
  • Kato, Toru
  • Yasuda, Koubun
RU2791705C2
INTRODUCTION OF CONSTRUCTED T CELLS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM CANCER 2017
  • Badi Benkhem
  • Braun Kristin E.
  • Formen Stiven Dzh.
  • Prajsmen Sol Dzh.
RU2757308C2

RU 2 770 001 C2

Authors

Vollera Deniel Attilio

Miller Dzheffri S.

Dates

2022-04-14Published

2016-10-06Filed